Pharmacotherapy
Clinician's Perspective: • Researchers identified a specific genetic variant in the GLP1R gene (GLP-1 receptor) (the primary cellular docking site for these drugs) that directly influences how much weight a person loses. • Individuals carrying a specific version of this gene (rs10305420) experienced an additional 0.76 kg of weight
Pharmacotherapy
Clinician's Perspective: • Modern anti-obesity medications (AOM) function by modulating central appetite signaling, delaying gastric emptying, or inhibiting lipid absorption in the gastrointestinal tract. • In Singapore, typical medical criterion for AOM treatment include a Body Mass Index (BMI) of 27.5 or higher in the presence of weight-related comorbidities
Pharmacotherapy
Clinician's Perspective: • Hormonal Mimicry: GLP-1 agonists function by mimicking the Glucagon-like peptide-1 hormone, a naturally occurring substance produced in the small intestine that regulates insulin and satiety (the feeling of fullness). • Glucose Modulation: These agents trigger insulin release and block glucagon secretion, effectively preventing blood sugar spikes and
Pharmacotherapy
Clinician's Perspective: • Combined Potency: Bupropion combined with Naltrexone demonstrated superior weight reduction compared to Bupropion monotherapy (the use of a single drug). • Absolute Weight Loss: The meta-analysis, involving over 22,000 participants, revealed a mean weight reduction of 3.67 kg across the intervention groups compared to controls.
Pharmacotherapy
Clinician's Perspective: • Synergistic Weight Loss: Combining phentermine and topiramate-ER (extended-release) provides a more robust weight reduction than either drug used alone by targeting different metabolic pathways. • Significant Results: In the EQUIP trial involving 1,267 participants, the high-dose group achieved an average weight loss of 14.4% of